ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sarina Tanimoto Sells 100,000 Shares of Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $9.34, for a total transaction of $934,000.00. Following the completion of the sale, the insider now directly owns 1,596,494 shares of the company’s stock, valued at $14,911,253.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Sarina Tanimoto also recently made the following trade(s):

• On Tuesday, April 16th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.28, for a total value of $928,000.00.
• On Friday, March 22nd, Sarina Tanimoto sold 2,343 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.02, for a total transaction of $21,133.86.
• On Thursday, March 14th, Sarina Tanimoto sold 444 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.00, for a total value of $3,996.00.
• On Wednesday, February 28th, Sarina Tanimoto sold 98,778 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.02, for a total value of $890,977.56.
• On Monday, February 26th, Sarina Tanimoto sold 700 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.01, for a total value of $6,307.00.

ARS Pharmaceuticals Trading Up 2.2 %

ARS Pharmaceuticals stock opened at $8.99 on Friday. The firm has a market capitalization of $871.08 million, a PE ratio of -15.44 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a 12-month low of $2.55 and a 12-month high of $11.27. The firm has a 50-day moving average price of $9.06 and a 200-day moving average price of $6.77.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its earnings results on Thursday, March 21st. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. As a group, sell-side analysts predict that ARS Pharmaceuticals, Inc. will post -0.69 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on SPRY shares. William Blair upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 20th. Wedbush reissued an “outperform” rating and set a $19.00 price objective on shares of ARS Pharmaceuticals in a research report on Monday, March 11th. Leerink Partnrs raised ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 5th. Finally, SVB Leerink raised ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $6.00 to $18.00 in a research report on Tuesday, March 5th.

Institutional Trading of ARS Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its position in ARS Pharmaceuticals by 22,300.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company’s stock worth $31,000 after acquiring an additional 5,575 shares in the last quarter. AJOVista LLC acquired a new stake in ARS Pharmaceuticals during the fourth quarter valued at approximately $43,000. Russell Investments Group Ltd. bought a new position in ARS Pharmaceuticals during the 1st quarter worth approximately $60,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of ARS Pharmaceuticals by 352.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company’s stock valued at $61,000 after acquiring an additional 8,652 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of ARS Pharmaceuticals during the 1st quarter valued at about $119,000. 68.16% of the stock is owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.